Florida is currently home to 3772 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Freedom-1 Study for Chronic Knee Pain
Recruiting
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Holy Cross Hospital, Inc, Fort Lauderdale, Florida
Conditions: Osteoarthritic Knee Pain
Generic Database of Very Low Birth Weight Infants
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Miami, Miami, Florida
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Follow-up Visit of High Risk Infants
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Miami, Miami, Florida
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Healthy Aging Through Movement
Recruiting
This study aims to examine the effectiveness of a supervised aerobic exercise program for persons with Opioid Use Disorder (OUD). Participants will be enrolled in a 12-week supervised aerobic exercise intervention.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
02/10/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Opioid Use Disorder
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
Recruiting
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Midland Florida clinical Research Center LLC, DeLand, Florida
Conditions: Diabetic Foot Ulcer
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: Baptist Medical Center Jacksonville, Jacksonville, Florida
Conditions: Vertebral Artery Stenosis
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Recruiting
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily act... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Peerbridge Health, Melbourne, Florida
Conditions: Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Recruiting
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Mid Florida Hematology and Oncology Center, Orange City, Florida
Conditions: Higher-risk Myelodysplastic Syndromes
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics
Recruiting
The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the m... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Acute Pancreatitis
High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.
Recruiting
A 12-week double-blind randomized control trial will be conducted among adults on hemodialysis (n=15) to determine the impact of liposomal curcumin in a high-protein product on inflammation markers and oxidative stress. Participants will be randomized via a computer-generator into either the control or intervention group. Participants in each group will be given a total of 38 g of a high protein product with or without 7 mls of liposomal curcumin for a total of 8 weeks. At baseline, weeks 8 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Chronic Kidney Disease 5D
Study of JK07 in Patients With Chronic Heart Failure
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/07/2025
Locations: Site 114, Hialeah, Florida
Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction